ACRS EBITDA | Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. (ACRS) EBITDA

2026-06-30: Basis Reported; EBITDA -$24.13M*; Operating income -$24.24M; Depreciation and amortization $107.00K*.
2026-03-31: Basis Reported; EBITDA -$22.09M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$22.63M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$17.04M*; Operating income -$17.15M; Depreciation and amortization $110.00K*.

Complete source-backed ebitda history.

Available history: 2015-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$24.13M*	-$24.24M	$107.00K*	$1.63M	-1481.34%*	$58.00K*	-$19.85M*	(m)	$18.07M	(m)	(m)
2026-03-31	Reported	-$22.09M	(m)	(m)	(m)	(m)	$13.00K	-$18.15M	(m)	$15.66M	(m)	(m)
2025-12-31	Reported	-$22.63M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$17.04M*	-$17.15M	$110.00K*	$3.30M	-516.49%*	$23.00K*	-$10.93M*	(m)	$13.03M	(m)	(m)
2025-06-30	Reported	-$18.29M*	-$18.41M	$114.00K*	$1.78M	-1029.49%*	$21.00K*	-$9.99M*	(m)	$11.45M	(m)	(m)
2025-03-31	Reported	-$17.96M	(m)	(m)	(m)	(m)	$43.00K	-$13.06M	(m)	$11.58M	(m)	(m)
2024-12-31	Reported	-$99.53M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$10.29M*	-$10.47M	$179.00K*	$4.35M	-236.82%*	$0.00*	$22.00M*	(m)	$5.96M	(m)	(m)
2024-06-30	Reported	-$12.61M*	-$12.85M	$242.00K*	$2.77M	-455.97%*	-$14.00K*	-$12.32M*	(m)	$8.76M	(m)	(m)
2024-03-31	Reported	-$18.69M	(m)	(m)	(m)	(m)	$135.00K	-$20.82M	(m)	$9.85M	(m)	(m)
2023-12-31	Reported	-$3.82M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$31.36M*	-$31.58M	$219.00K*	$9.28M	-337.84%*	$84.00K*	-$24.56M*	(m)	$23.88M	(m)	(m)
2023-06-30	Reported	-$31.60M*	-$31.82M	$218.00K*	$1.87M	-1690.58%*	$231.00K*	-$20.65M*	(m)	$25.27M	(m)	(m)
2023-03-31	Reported	-$29.72M	(m)	(m)	(m)	(m)	$553.00K	-$26.35M	(m)	$22.59M	(m)	(m)
2022-12-31	Reported	-$28.89M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$20.68M*	-$20.87M	$193.00K*	$19.02M	-108.74%*	$150.00K*	-$7.82M*	(m)	$23.66M	(m)	(m)
2022-06-30	Reported	-$20.79M*	-$20.99M	$206.00K*	$1.53M	-1360.47%*	$186.00K*	-$19.67M*	(m)	$18.78M	(m)	(m)
2022-03-31	Reported	-$18.7M	(m)	(m)	(m)	(m)	$164.00K	-$20.97M	(m)	$14.31M	(m)	(m)
2021-12-31	Reported	-$22.7M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$20.10M*	-$20.30M	$191.00K*	$1.66M	-1211.81%*	$56.00K*	-$10.61M*	(m)	$13.98M	(m)	(m)
2021-06-30	Reported	-$17.76M*	-$18.01M	$247.00K*	$1.82M	-973.63%*	(m)	-$12.22M*	(m)	$7.90M	(m)	(m)
2021-03-31	Reported	-$28.24M	(m)	(m)	(m)	(m)	(m)	-$12.23M	(m)	$7.84M	(m)	(m)
2020-12-31	Reported	-$14.01M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$9.87M*	-$10.46M	$591.00K*	$1.45M	-681.44%*	$304.00K*	-$12.15M*	(m)	$6.24M	(m)	(m)
2020-06-30	Reported	-$10.78M*	-$11.38M	$606.00K*	$2.05M	-526.64%*	$17.00K*	-$10.82M*	(m)	$6.47M	(m)	(m)
2020-03-31	Reported	-$14.93M	(m)	(m)	(m)	(m)	$124.00K	-$6.80M	$1.27M	$7.68M	(m)	(m)
2019-12-31	Reported	-$17.23M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$21.23M*	-$22.86M	$1.63M*	$983.00K	-2159.92%*	$822.00K*	-$23.36M*	$826.00K	$16.18M	(m)	(m)
2019-06-30	Reported	-$41.37M*	-$43.60M	$2.23M*	$886.00K	-4669.19%*	$241.00K*	-$21.38M*	$2.70M	$17.52M	(m)	(m)
2019-03-31	Reported	-$24.83M	(m)	(m)	(m)	(m)	$284.00K	-$31.32M	$2.78M	$19.64M	(m)	(m)
2018-12-31	Reported	-$23.09M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$20.96M*	-$21.34M	$384.00K*	$1.12M	-1874.60%*	$560.00K*	-$29.86M*	(m)	$15.19M	(m)	(m)
2018-06-30	Reported	-$31.66M*	-$31.98M	$315.00K*	$3.68M	-861.34%*	$352.00K*	-$21.83M*	$1.18M	$13.98M	(m)	(m)
2018-03-31	Reported	-$30.73M	(m)	(m)	(m)	(m)	$298.00K	-$21.87M	(m)	$13.61M	(m)	(m)
2017-12-31	Reported	-$7.2M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$18.64M*	-$18.76M	$116.00K*	$684.00K	-2725.15%*	$270.00K*	-$13.71M*	(m)	$10.86M	(m)	(m)
2017-06-30	Reported	-$15.24M*	-$15.29M	$55.00K*	(m)	(m)	$193.00K*	-$10.08M*	(m)	$7.96M	(m)	(m)
2017-03-31	Reported	-$12.88M	(m)	(m)	(m)	(m)	$195.00K	-$12.66M	(m)	$7.77M	(m)	(m)
2016-12-31	Reported	-$11.59M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	(m)	-$10.81M	(m)	(m)	(m)	$64.00K*	-$9.90M*	(m)	$7.16M	(m)	(m)
2016-06-30	Reported	(m)	-$12.99M	(m)	(m)	(m)	$66.00K*	(m)	(m)	$9.84M	(m)	(m)
2016-03-31	Reported	(m)	-$13.14M	(m)	(m)	(m)	$40.00K	(m)	(m)	$9.54M	(m)	(m)
2015-09-30	Reported	(m)	-$10.64M	(m)	(m)	(m)	$133.00K*	(m)	(m)	$9.41M	(m)	(m)
2015-06-30	Reported	(m)	-$2.60M	(m)	(m)	(m)	$165.00K*	(m)	(m)	$1.79M	(m)	(m)
2015-03-31	Reported	(m)	-$2.63M	(m)	(m)	(m)	$77.00K	(m)	(m)	$1.74M	(m)	(m)
2014-09-30	Reported	(m)	-$2.66M	(m)	(m)	(m)	(m)	(m)	(m)	$2.10M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$75.92M	(m)	(m)	(m)	(m)	$111.00K	-$47.11M	(m)	$52.65M	(m)	(m)
2024-12-31	Reported	-$141.13M	(m)	(m)	(m)	(m)	$121.00K	-$20.07M	(m)	$33.59M	(m)	(m)
2023-12-31	Reported	-$96.49M	(m)	(m)	(m)	(m)	$1.31M	-$78.33M	(m)	$98.38M	(m)	-$367.00K
2022-12-31	Reported	-$89.06M	(m)	(m)	(m)	(m)	$605.00K	-$67.57M	(m)	$77.81M	(m)	(m)
2021-12-31	Reported	-$88.8M	(m)	(m)	(m)	(m)	$308.00K	-$52.13M	(m)	$43.81M	(m)	(m)
2020-12-31	Reported	-$49.59M	(m)	(m)	(m)	(m)	$453.00K	-$38.63M	(m)	$29.34M	(m)	-$182.00K
2019-12-31	Reported	-$104.65M	(m)	(m)	(m)	(m)	$1.61M	-$96.44M	(m)	$64.17M	(m)	(m)
2018-12-31	Reported	-$82.9M	(m)	(m)	(m)	(m)	$1.36M	-$100.81M	(m)	$60.84M	(m)	(m)
2017-12-31	Reported	-$53.96M	(m)	(m)	(m)	(m)	$1.24M	-$54.66M	(m)	$35.80M	(m)	-$1.83M
2016-12-31	Reported	-$48.45M	(m)	(m)	(m)	(m)	$232.00K	-$34.60M	(m)	$33.48M	(m)	(m)
2015-12-31	Reported	-$20.58M	(m)	(m)	(m)	(m)	$507.00K	-$20.37M	(m)	$15.34M	(m)	(m)
2014-12-31	Reported	(m)	-$8.53M	(m)	(m)	(m)	$417.00K	(m)	(m)	$6.51M	(m)	(m)
2013-12-31	Reported	(m)	-$5.26M	(m)	(m)	(m)	(m)	(m)	(m)	$3.49M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Olema Pharmaceuticals, Inc. (OLMA)	United States	$0.790B	-5.35
GERON CORP (GERN)	United States	$0.803B	-12.14
Wave Life Sciences, Inc. (WVE)		$0.780B	-5.56
Design Therapeutics, Inc. (DSGN)	United States	$0.766B	-12.78
GYRE THERAPEUTICS, INC. (GYRE)	United States	$0.818B	-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)	United States	$0.823B	-17.48
Obsidian Therapeutics, Inc. (OBX)	United States	$0.829B
Faeth Therapeutics, Inc. (FTH)	United States	$0.750B
Immix Biopharma, Inc. (IMMX)	United States	$0.837B	-18.44
Avalo Therapeutics, Inc. (AVTX)	United States	$0.842B	-9.74